Lilly marks 150 years as Indiana study puts its state economic impact at nearly $15.6 billion
The anniversary numbers describe Lilly's role in Indiana's economy and its growing U.S. manufacturing base, not any change in how its medicines are priced or supplied.
Eli Lilly and Company marked its 150th anniversary with a ceremony in Indianapolis on Tuesday, the same week an Indiana University study reported that the drugmaker's direct operations add nearly $15.6 billion a year to Indiana's economy [1][2][3].
Colonel Eli Lilly, a chemist and Civil War veteran, founded the company on May 10, 1876, in a two-story building near Meridian and Pearl streets, aiming to make high-quality medicines [2]. The world's first commercially available insulin product followed in 1923 [2].
Tuesday's "150 Years of Medicine" event was emceed by former Indianapolis Colts quarterback Peyton Manning [1][2]. Mayor Joe Hogsett proclaimed "Eli Lilly and Company Week" in the city and said Indianapolis "would not be the same wonderful, vibrant city that it is today without the impact of Eli Lilly and Company" [1]. Gov. Mike Braun said, "We are blessed to have this company here in Indiana. Forty-nine other states would give anything to have a company like Eli Lilly" [2].
The study was prepared by the Indiana Business Research Center at Indiana University's Kelley School of Business, which worked with Lilly on the analysis [3]. It found that Lilly's annual direct operations contributed nearly $15.6 billion to Indiana's gross domestic product, 2.7% of the state's total economic output [2][3]. Lilly reports 14,700 Indiana employees; their supply-chain purchases and household spending support an additional 31,900 jobs, for a total employment impact of about 46,600 [3]. Every direct Lilly job supports 2.17 jobs at other Hoosier employers, according to the report's employment multiplier of 3.17 [2][3]. Average annual compensation across the 46,600 jobs is $142,130, more than 70% above the average for all Indiana jobs [3]. Counting capital spending as well, the report puts Lilly's combined GDP impact at nearly $20.7 billion, or 3.6% of state output [3].
Some figures differ by outlet. Axios reported the company employs "nearly 15,000 Hoosiers" and contributes "more than $15 billion," about 3% of output [1]. For a celebration planned for employees and families later in the week, Axios reported an expected crowd of more than 20,000, while the Indianapolis Business Journal reported 22,000 [1][2].
The report also covers Lilly's $18 billion LEAP Research and Innovation District campus in Boone County, to be built over a five-year construction phase expected to finish by the end of 2027 [3]. Once fully operational, Lilly plans 1,600 workers there, for a total employment impact of about 4,880 jobs [3]. By 2030, the report estimates Lilly's Indiana employment footprint will reach 52,400 jobs and its total state GDP impact will approach $22.5 billion in 2026 dollars [3].
CEO David Ricks said Lilly's medicine pipeline "is the strongest in our history" [2]. "This may be the beginning of the biggest sustained upswing in our history," he said. "It may also be just another peak in a series of peaks and valleys along the way. We don't get to know which, but we do get to choose how to act" [1][2].
Why it matters for patients
Lilly is the maker of Zepbound, its obesity drug, and its shares have risen more than 75% since Zepbound launched two years ago [1]. Most of the anniversary numbers measure the company's footprint in one state rather than the medicines themselves. Still, the report describes a large U.S. manufacturing and research build-out: more than $50 billion in U.S.-based capital investments announced since 2020, including the $18 billion Boone County campus [1][3].
Whether that expansion changes the supply or the price of any specific medicine has not been disclosed in these reports. The 2030 employment and GDP figures are projections, and the economic analysis was done with Lilly's cooperation, based on company spending data [3]. The report also notes Lilly's $57.5 million commitment to Lilly Scholars programs at Ivy Tech Community College and Purdue University [3].
What happens next
Lilly's Boone County construction is expected to be completed by the end of 2027, with the campus fully operational by 2030 and 1,600 workers employed there [1][3]. The report projects Lilly's Indiana employment will reach 52,400 jobs by 2030 [3]. Separately, Axios reported Lilly has made six acquisitions so far this year, after about 40 in 2025, largely aimed at adding to its drug pipeline [1].
Images from the sources
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.